This prompted these concerned clinicians to conduct a large retrospective matched cohort study of their patients at Massachusetts Eye and Ear in Boston
Ln da tr hn nhn thy np nhn mn mng, da b sn chn, da mm mi v sng ng, gip ln da trng tr hn, mn mng hn trng tr trung hn
In TRIUMPH-4 trials, 20.9% of patients on 12mg experienced these symptoms, and TRIUMPH-1 confirmed dysesthesia at 12.5% in the general obesity population
The sensitivity is present most of the time rather than intermittently
Not yet widely available for clinical use Long-term safety data are still limited Digestive side effects remain common in clinical studies Until more evidence becomes available, Retatrutide should be viewed as a promising investigational peptide rather than an established treatment
Semaglutide has many proven health benefits however it is not naive to side effects